HIV Part 2 Wk 3 Flashcards
After fusion, capsid trafficking to the nucleus and virus genome replication begin
HIV replication cycle - genome replication is via a dsDNA intermediate
tRNA (in capsid) anneals to primer binding site (PBS) close to 5’end of genome
Reverse Transcriptase (DNA polymerase) synthesises a short (-) DNA strand from 3’ end (-OH) of tRNA primer = complementary to R & U5 sequences
Copied region of RNA genome degraded by virus ribonuclease (HIV=part of RT)
Newly synthesised (-)DNA strand re-anneals at 3’ R sequence
= TEMPLATE SWITCHING
RT continues to extend (-)DNA strand = all genome sequences copied, to PBS region
3’ end of RNA genome (R, U3) degraded by virus ribonuclease
RT starts to synthesis 2nd strand
= (+)DNA, synthesised from 3’-OH at end of PPT sequence (polypurine tract)
All remaining RNA genome sequences degraded by virus ribonuclease
Newly synthesised (+)DNA strand re-anneals at 5’ PBS sequence
= TEMPLATE SWITCHING RESULT is duplication of sequences = (U3-R-U5) at both ends
RT final steps synthesises both DNA strands
Both stands act as primer for their own extension
and as template for complementary strand synthesis
Compare fully copied, dsDNA genome intermediate with original RNA genome
dsDNA copy has duplicated ends = Long Terminal Repeats (LTRs)
Antiviral drug target – reverse transcriptase
Azidothymidine - (Zidovudine / Retrovir)
Lamivudine- (3TC)
Emtricitabine (FTA/Emtriva)
Tenofovir disoproxil - (viread)
Nucleotide analogue RT inhibitor NtRTI
NRTI and NtRTi mechanism of action – DNA chain terminators
Antiviral drug target – non-nucleoside reverse transcriptase inhibitors NNRTI
nevirapine (viramune)
rilpivirine (Edurant)
NNTRIs dont required Phosphorylation step
Bind RT at discrete site
Inhibits RT polymerase enzyme activity
Chain terminators against Reverse Transcriptase have prophylactic activity
Tenofovir disoproxil
Nucleotide analogue (NtRTI)
Chain terminators against Reverse Transcriptase have prophylactic activity
Emtricitabine
Nucleoside analogue (NRTI)
2012 meta-analysis of clinical trials
Reduce risk of acquiring HIV in high-risk individuals
Tenofovir = 6% reduction in risk
Tenofovir + Emtricitabine = 51% reduction in risk
Tenofovir + Emtricitabine = Truvada - used for therapeutic treatment (HIV+)
and Pre-exposure prophylaxis (PrEP; HIV-)
dsDNA intermediate integrates into cell chromosome
Virus genome intermediate dsDNA - held within a partially opened capsid
Traffics to nucleus bound to
-polymerase enzyme complex, integrase enzyme
-molecules of the virus matrix, Vpr + Nef proteins
=Pre-integration complex (PIC)
Capsid deforms to pass through nuclear pores
dsDNA intermediate integrates into cell chromosome
Integrase - degrades 3’ ends of virus DNA to expose reactive 3’-OH
- cuts cellular DNA at target sites (predominantly euchromatin regions)
5’ overhangs of the DNAs anneal and are ligated Cell & virus enzymes ligate DNAs
integrated DNA genome is referred to as a provirus
Antiviral drug target – integrase
Raltegravir (Isentriss)
Bictegravir (BIC)
Dolutegravir (Tivicay)
Elvitegravir (EVG)
Integrase inhibitors target the catalytic site of HIV integrase to inhibit the viral integration of proviral DNA into host genomes
HIV Provirus transcription – gag and gag-pol polyproteins
Infected cell transcribes full length RNAs from integrated provirus (dsDNA)
- enzyme = cellular RNA polymerase II
- promoter / enhancer sequences are in the 5’ LTR (U3 sequences)
- polyadenylation (terminator) signal is in the 3’ UTR (U5 sequences)
Full-length messenger RNA transcripts with = (+)ssRNA with 5’ cap, 3’ polyA tail
A. Most act as normal mRNAs = bind ribosomes for translation of gag and pol proteins
B. Some traffic to plasma membrane, as new virus genomes for virion assembly
HIV Provirus transcription – gag and gag-pol polyproteins